Robert Pirker

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer
    Robert Pirker
    Department of Internal Medicine I, University of Vienna Medical School, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Lung Cancer 38:S53-5. 2002
  2. ncbi request reprint Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer
    R Pirker
    Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Lung 184:279-85. 2006
  3. ncbi request reprint Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:3892-8. 2007
  4. doi request reprint EGFR-directed monoclonal antibodies in non-small cell lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Target Oncol 8:47-53. 2013
  5. pmc Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
    Robert Pirker
    Medical University Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Support Care Cancer 21:987-92. 2013
  6. doi request reprint Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study
    R Pirker
    Department of Medicine I, Medical University Vienna, Vienna, Austria
    Lung Cancer 77:376-82. 2012
  7. doi request reprint EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    Robert Pirker
    Department of Medicine I, Medical University Vienna, Vienna, Austria
    Lancet Oncol 13:33-42. 2012
  8. ncbi request reprint Targeted therapies in lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Curr Pharm Des 15:188-206. 2009
  9. ncbi request reprint Darbepoetin alfa for the treatment of cancer-related anemia: an update
    Robert Pirker
    Medical University Vienna, Department of Internal Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Rev Anticancer Ther 4:735-44. 2004
  10. ncbi request reprint Therapy of advanced non-small-cell lung cancer (take home message)
    Robert Pirker
    Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Lung Cancer 45:S259-62. 2004

Detail Information

Publications45

  1. ncbi request reprint Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer
    Robert Pirker
    Department of Internal Medicine I, University of Vienna Medical School, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Lung Cancer 38:S53-5. 2002
    ..Thus three-drug combinations have not convincingly been demonstrated to be superior to two-drug combinations and should not be considered as standard protocols in advanced NSCLC...
  2. ncbi request reprint Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer
    R Pirker
    Division of Oncology, Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Lung 184:279-85. 2006
    ..Four patients (15%) had febrile neutropenia. Full-dose, on-schedule dose-dense ACE chemotherapy is feasible with once-per-cycle pegfilgrastim support in extensive SCLC...
  3. ncbi request reprint Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:3892-8. 2007
    ..The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT)...
  4. doi request reprint EGFR-directed monoclonal antibodies in non-small cell lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Target Oncol 8:47-53. 2013
    ..Cetuximab is also studied in combination with chemoradiotherapy in patients with locally advanced NSCLC...
  5. pmc Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
    Robert Pirker
    Medical University Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Support Care Cancer 21:987-92. 2013
    ..The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy...
  6. doi request reprint Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study
    R Pirker
    Department of Medicine I, Medical University Vienna, Vienna, Austria
    Lung Cancer 77:376-82. 2012
    ..The FLEX study is registered with ClinicalTrials.gov, number NCT00148798...
  7. doi request reprint EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    Robert Pirker
    Department of Medicine I, Medical University Vienna, Vienna, Austria
    Lancet Oncol 13:33-42. 2012
    ..To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients...
  8. ncbi request reprint Targeted therapies in lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Curr Pharm Des 15:188-206. 2009
    ..In small cell lung cancer (SCLC), targeted therapies have also been studied but no clinical benefit could be demonstrated for these agents...
  9. ncbi request reprint Darbepoetin alfa for the treatment of cancer-related anemia: an update
    Robert Pirker
    Medical University Vienna, Department of Internal Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Rev Anticancer Ther 4:735-44. 2004
    ..This review provides an overview of clinical trial results, particularly those exploring flexible, extended dosing schedules...
  10. ncbi request reprint Therapy of advanced non-small-cell lung cancer (take home message)
    Robert Pirker
    Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Lung Cancer 45:S259-62. 2004
    ..This goal is usually achieved by one or more of the following treatment modalities: chemotherapy, radiotherapy, special palliative interventions and general supportive care measures...
  11. doi request reprint Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide
    Robert Pirker
    Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 26:2342-9. 2008
    ....
  12. ncbi request reprint Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy
    Robert Pirker
    Department of Internal Medicine I, Medical University Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Lung Cancer 55:89-94. 2007
    ..Epoetin beta was well tolerated. This early intervention strategy with epoetin beta 30,000 IU once weekly is an effective and well-tolerated therapy for anemia in patients with lung cancer...
  13. ncbi request reprint Safety considerations for erythropoietin treatment in patients with cancer
    Robert Pirker
    Lung Cancer, Medical University of Vienna, Department of Internal Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Opin Drug Saf 6:63-9. 2007
    ..However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study...
  14. doi request reprint Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer
    Robert Pirker
    Department of Internal Medicine I, Medical University of Vienna, Austria
    Clin Lung Cancer 9:S109-15. 2008
    ..Two phase III trials with chemotherapy with or without cetuximab have been performed in patients with advanced NSCLC. Other EGFR-directed MoAbs and TKIs are in earlier stages of clinical development...
  15. doi request reprint Monoclonal antibodies against EGFR in non-small cell lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Austria
    Crit Rev Oncol Hematol 80:1-9. 2011
    ..Matuzumab and panitumumab have also been evaluated in phase II trials. Necitumumab is currently evaluated in combination with chemotherapy in two randomized phase III trials...
  16. doi request reprint Erythropoiesis-stimulating agents in patients with cancer: update on safety issues
    Robert Pirker
    Medical University of Vienna, Department of Medicine I, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Opin Drug Saf 8:515-22. 2009
    ..Hypertension and thromboembolic events are the main side effects. The association between erythropoietic proteins and clinical outcome including survival warrants further studies...
  17. doi request reprint Therapy of small cell lung cancer with emphasis on oral topotecan
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Lung Cancer 70:7-13. 2010
    ..Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer...
  18. doi request reprint Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    J Thorac Oncol 5:1706-13. 2010
    ..Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations...
  19. doi request reprint Chemotherapy of advanced non-small cell lung cancer
    Robert Pirker
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Front Radiat Ther Oncol 42:157-63. 2010
    ..Finally, the efficacy of new anticancer treatments should be assessed by several clinical endpoints with overall survival remaining the most important endpoint in patients with advanced NSCLC...
  20. ncbi request reprint Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group
    Martin Filipits
    Department of Internal Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 23:1161-8. 2005
    ..Therefore, we determined the impact of MRP1 expression on the clinical outcome of adjuvant therapy in patients with early-stage breast cancer...
  21. doi request reprint Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    Lancet 373:1525-31. 2009
    ..We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer...
  22. ncbi request reprint Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy
    Margaretha Rudas
    Department of Pathology, University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 81:149-57. 2003
    ..Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression...
  23. ncbi request reprint Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer
    Gudrun Pohl
    Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Lung Cancer 54:63-7. 2006
    ..05). In conclusion, the TIP regimen shows activity and good tolerance as induction chemotherapy in patients with locally advanced NSCLC...
  24. ncbi request reprint High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin
    Gudrun Pohl
    Department of Medicine I, Clinical Division of Oncology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Clin Oncol 21:3594-600. 2003
    ..To determine the predictive value of p27Kip1 in premenopausal women with early-stage hormone receptor-positive breast cancer...
  25. ncbi request reprint Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 25:2735-40. 2007
    ..The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT...
  26. ncbi request reprint Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy
    Gudrun Pohl
    Department of Internal Medicine 1, Division of Oncology, University Hospital, Vienna, Austria
    Breast Cancer Res Treat 78:97-103. 2003
    ....
  27. doi request reprint EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases
    Katharina Schmid
    Clinical Institute of Pathology and Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Clin Cancer Res 15:4554-60. 2009
    ..The present study compared the mutational status of EGFR, KRAS, and BRAF in primary tumors with the one in corresponding lymph node metastases...
  28. ncbi request reprint Anemia in lung cancer: clinical impact and management
    Robert Pirker
    Department of Internal Medicine I, University of Vienna, Austria
    Clin Lung Cancer 5:90-7. 2003
    ..Oncologists must be aware of the clinical relevance of anemia and offer adequate treatment options to their patients...
  29. ncbi request reprint Darbepoetin alfa: potential role in managing anemia in cancer patients
    Robert Pirker
    Department of Internal Medicine I, University of Vienna, Austria
    Expert Rev Anticancer Ther 2:377-84. 2002
    ..Thus, darbepoetin alfa has the potential to improve supportive care and thereby, cancer patients' quality of life, and might also impact on treatment outcome...
  30. doi request reprint Predictive markers in the adjuvant therapy of non-small cell lung cancer
    Martin Filipits
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Lung Cancer 74:355-63. 2011
    ..After standardization of these tests and further validation studies, biomarkers might allow individualizing adjuvant treatment in patients with completely resected NSCLC in the future...
  31. ncbi request reprint Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma
    Beata Herberger
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 13:4795-9. 2007
    ..The purpose of our study was to determine the prognostic value of activated mTOR (p-mTOR) in patients with biliary tract adenocarcinoma (BTA), in order to strengthen the rationale for targeted therapy of BTA using mTOR inhibitors...
  32. ncbi request reprint Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer
    Gerwin Heller
    Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Breast Cancer Res Treat 103:283-91. 2007
    ..011, P = 0.02). Our findings suggest that TSLC1 and DAL-1 are involved in the pathogenesis of breast cancer and are frequently inactivated by methylation...
  33. ncbi request reprint Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas
    M Filipits
    Division of Oncology, Department of Internal Medicine I, University of Vienna, Austria
    Clin Cancer Res 6:3417-23. 2000
    ..Thus, the reversal of LRP-mediated drug resistance may improve clinical outcome in diffuse large B-cell lymphoma in the future...
  34. ncbi request reprint Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer
    Jean Yves Douillard
    Department of Medical Oncology, institut de cancérologie de l Ouest, Centre Rene Gauducheau, Saint Herblain, France Department of Medicine I, Medical University of Vienna, Vienna, Austria HOPE Directorate, St James s Hospital, Dublin, Ireland Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom Institute of Pathology, University of Witten Herdecke and HELIOS Hospital Wuppertal, Wuppertal, Germany Global Biostatistics, Biomarker Technologies and Operations, and Translational Innovation Platform Oncology, Merck KGaA, Darmstadt, Germany and University Health Network, Department of Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
    J Thorac Oncol 9:717-24. 2014
    ..We assessed whether the treatment effect was also modulated in FLEX study patients by tumor EGFR mutation status...
  35. ncbi request reprint Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma
    Martin Filipits
    Department of Internal Medicine I, Division of Oncology, University of Vienna, A 1090 Vienna, Austria
    Clin Cancer Res 8:729-33. 2002
    ..In conclusion, high cyclin D3 expression is an independent predictive and prognostic factor associated with poor clinical outcome in patients with diffuse large B-cell lymphoma...
  36. ncbi request reprint New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer
    R Malayeri
    Division of Oncology, Department of Internal Medicine I, University of Vienna Medical School, Austria
    Onkologie 24:416-21. 2001
    ..Second-line chemotherapy prolongs survival in selected patients and should be particularly offered to patients with good performance status...
  37. pmc High D-dimer levels are associated with poor prognosis in cancer patients
    Cihan Ay
    Clinical Division of Hematology and Hemostaseology Department of Medicine I, Vienna, Austria
    Haematologica 97:1158-64. 2012
    ..Increased levels of D-dimer, which is a degradation product of cross-linked fibrin, indicate a global activation of hemostasis and fibrinolysis...
  38. ncbi request reprint Adjuvant and induction chemotherapy in non-small cell lung cancer
    R Pirker
    Department of Internal Medicine I, University of Vienna, Austria
    Ann Oncol 10:71-6. 1999
    ..Thus adjuvant chemotherapy with both improved chemotherapy protocols and improved anti-emetics is currently re-evaluated in several randomised trials on large patient populations...
  39. ncbi request reprint [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]
    Wolfgang Hilbe
    Medizinische Universitat Innsbruck, Klinische Abteilung für Allgemeine Innere Medizin, Schwerpunkt Onkologie, Innsbruck, Austria
    Wien Klin Wochenschr 119:259-66. 2007
  40. ncbi request reprint Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
    Johan Vansteenkiste
    Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Invest New Drugs 23:263-9. 2005
    ..The present study did not show any advantage, in response rate or secondary endpoints, with aprinocarsen; however, the toxicity was not unduly increased, and aprinocarsen regimen was safely administered...
  41. ncbi request reprint Erythropoietin in cancer: an update
    Jozsef Tovari
    Department of Tumor Biology, National Koranyi Institute of Pulmonology, Piheno u 1, Budapest, H 1529, Hungary
    Curr Mol Med 8:481-91. 2008
    ..The current paper provides an update on the biology of EPO, and discusses its utility in the treatment of cancer patients...
  42. ncbi request reprint Highly refractory acute myeloid leukemia
    Wolfgang Füreder
    Division of Hematology and Hemostaseology, The University of Vienna, Austria
    Wien Klin Wochenschr 116:561-4. 2004
    ..Overall, patients with highly refractory AML are characterized by a high incidence of complex cytogenetic aberrations and marked expression of drug transporters...
  43. ncbi request reprint Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Johan Vansteenkiste
    Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Natl Cancer Inst 94:1211-20. 2002
    ..This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy...
  44. ncbi request reprint Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer
    Pieter E Postmus
    Department of Pulmonary Diseases, Vrije Universiteit Medical Cetner, Amsterdam, Netherlands
    Lung Cancer 42:S3-6. 2003
  45. ncbi request reprint DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...